Documentation Centre

 

 

  of 578 Next page

Go to page: of

Screenshot Date Categories Title Author Format
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388:2665-2712 March 22, 2017 A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388:2665-2712 Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Gimenez-Roqueplo AP, Hering D, López-Jaramillo P, Martinez F, Perkovic V, Rietzschel ER, Schillaci G, Schutte AE, Scuteri A, Sharman JE, Wachtell K, Wang JG Key Publications
Exercise cardiac power and the risk of coronary heart disease and cardiovascular mortality in men. Ann Med. 2016;48:625-630 March 17, 2017 Exercise cardiac power and the risk of coronary heart disease and cardiovascular mortality in men. Ann Med. 2016;48:625-630 Kurl S, Mäkikallio T, Jae SY, Ronkainen K, Laukkanen JA Key Publications
Temporal changes in the association between modifiable risk factors and coronary heart disease incidence. JAMA. 2016;316:2041-2043 March 06, 2017 Temporal changes in the association between modifiable risk factors and coronary heart disease incidence. JAMA. 2016;316:2041-2043 Navar AM, Peterson ED, Wojdyla D, Sanchez RJ, Sniderman AD, D'Agostino RB Sr, Pencina MJ Key Publications
Impact of hypertension on cognitive function: A scientific statement from the American Heart Association. Hypertension. 2016;68:e67-e94 February 20, 2017 Impact of hypertension on cognitive function: A scientific statement from the American Heart Association. Hypertension. 2016;68:e67-e94 Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB et al. Key Publications
Cardiovascular risk factors and masked hypertension: The Jackson Heart Study. Hypertension. 2016;68:1475-1482 February 17, 2017 Cardiovascular risk factors and masked hypertension: The Jackson Heart Study. Hypertension. 2016;68:1475-1482 Bromfield SG, Shimbo D, Booth JN 3rd, Correa A, Ogedegbe G, Carson AP, Muntner P. Key Publications
Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension. 2016;68:1349-1354 February 17, 2017 Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension. 2016;68:1349-1354 Hwang AY, Dave C, Smith SM Key Publications
Genomic and metabolomic profile associated to clustering of cardio-metabolic risk factors. PLoS One. 2016;11:e0160656 February 06, 2017 Genomic and metabolomic profile associated to clustering of cardio-metabolic risk factors. PLoS One. 2016;11:e0160656 Marrachelli VG, Rentero P, Mansego ML, Morales JM, Galan I, Pardo-Tendero M, Martinez F, Martin-Escudero JC, Briongos L, Chaves FJ, Redon J, Monleon D Key Publications
Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes. J Hypertens. 2016;34:2376-2382 February 01, 2017 Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes. J Hypertens. 2016;34:2376-2382 Dempsey PC, Sacre JW, Larsen RN, Straznicky NE, Sethi P, Cohen ND, Cerin E, Lambert GW, Owen N, Kingwell BA, Dunstan DW Key Publications
Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm&#8201;hg target? An antagonist view from the HOPE-3 trial (Heart Outcomes Evaluation-3). Circulation. 2016;134:1311-1313 January 30, 2017 Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm hg target? An antagonist view from the HOPE-3 trial (Heart Outcomes Evaluation-3). Circulation. 2016;134:1311-1313 Lonn EM, Yusuf S Key Publications
Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm&#8201;hg target? A protagonist view from the SPRINT trial (Systolic Blood Pressure Intervention Trial). Circulation. 2016;134:1308-1310 January 27, 2017 Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mm hg target? A protagonist view from the SPRINT trial (Systolic Blood Pressure Intervention Trial). Circulation. 2016;134:1308-1310 Oparil S, Lewis CE Key Publications

  of 578 Next page

Go to page: of